Wednesday, October 12, 2022 8:38:20 PM
When it comes to timelines, I've yet to see a biotech I was involved in meet their timelines when they gave precise dates, and in most cases they're no more specific than our management where they "HOPE" to have this or that done at some time. I've yet to see a CEO or senior manager that didn't think that things could be done faster than is possible. Every task looks easy when others are doing it, when you have to do it yourself you often learn it's not as easy as you thought.
I'm not suggesting our management is perfect, they're far from it, but they're getting the job done. Some mngt. may have done it better, but others would have been belly up by now, we're actually in a very strong position, though we certainly could use some additional funds.
I know people don't like dilution, I don't mind it if it's done properly. I believe once the news is out and we have the Annual Meeting our share price will be at least a few dollars, perhaps over $5. At that point bringing in say $100 million with dilutive funding isn't so terrible and would position the company beautifully for gaining the approval from the 4 regulators and expanding the trials to take DCVax-L into additional indications and getting DCVax-Direct into pivotal trials in several indications. I believe the likelihood of a partnership or buyout at any time after the share price is above $5 and could warrant an offering that's in double digits. If it's a partnership I believe it will bring all the funding that will be needed in the foreseeable future. If we're bought out, that's it, the only choice we may have is taking cash, or stock in the company purchasing us. I much prefer a partnership.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
